Filing summary
Entity and period: The supplied filing is Synaptogenix, Inc.’s Form 10-K for the fiscal year ended December 31, 2020, signed March 30, 2021. It does not identify TAO Synergies Inc.; confirm that this is the intended filing. This is an annual report, not a standalone Q4 report. 2020 results combine the business’s pre-spin-off history under Neurotrope with Synaptogenix’s brief period as an independent company from December 7.
Business context and development
Synaptogenix is a pre-revenue biopharmaceutical company primarily developing bryostatin-1 for Alzheimer’s disease (AD), with earlier-stage work involving other neurological conditions. Its lead program is based on activating PKCε. The company depends on licensed technology, outside clinical vendors, and third-party drug supply.
Financial performance and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $11.16 million | $15.51 million |
| Research and development | $3.07 million | $5.67 million |
| General and administrative, including related-party expense | $8.09 million | $9.84 million |
| Net loss before deemed dividend | $12.70 million | $15.13 million |
| Net loss attributable to common shareholders | $15.13 million | $15.13 million |
| Cash used in operating activities | $8.10 million | $11.89 million |
The $2.43 million difference between 2020 net loss and loss attributable to common shareholders reflects a deemed dividend from shares and warrants issued in connection with the spin-off. The statements also record $1.70 million of non-cash warrant amendment expense. The MD&A contains an inconsistent description of 2020 net loss; the audited statements distinguish net loss of $12.70 million from common-shareholder loss of $15.13 million.
At year-end, cash and cash equivalents were $5.80 million, current assets $6.73 million, current liabilities $1.61 million, working capital $5.12 million, and total assets $6.75 million. No debt balance is presented. There is no meaningful operating margin because the company had no revenue. The company reported $8.10 million of operating cash use and $5,413 of capital expenditures.
After year-end, a January 2021 private placement generated approximately $14.0 million gross and $12.54 million net proceeds. Management said cash resources, including the financing and expected NIH grant reimbursements, should fund at least 12 months of projected operations from the filing date. The filing also says further capital will be needed for later trials and development.
Material changes and significant items
- Research and development expense fell 45.9% year over year, principally as spending on the prior confirmatory trial declined; the company expected R&D expense to rise as the new Phase 2 trial progressed.
- General and administrative expense declined overall, but legal expense rose to $2.21 million from $0.70 million, largely due to strategic planning and the spin-off. Non-cash stock compensation also declined.
- Synaptogenix became independent on December 7, 2020, following Neurotrope’s spin-off. Year-end cash was affected by a roughly $20.0 million transfer to Petros in connection with the merger, offset in part by parent-company transfers.
- The January 2021 placement involved substantial potential dilution: investors received common shares or pre-funded warrants plus Series E and F warrants. The filing reports 14,032,516 common shares outstanding as of March 19, 2021.
Clinical outlook, risks, and contingencies
- The confirmatory Phase 2 AD trial failed to achieve statistical significance on its primary endpoint. At week 13, mean SIB scores increased 1.3 points with bryostatin and 2.1 with placebo, with no significant between-group difference. A post-hoc analysis in a moderate-severity subgroup showed improvement from baseline in both arms; the treatment-versus-placebo difference was not significant (p=0.2727). These analyses do not establish efficacy.
- A further Phase 2 study was initiated in 2020, targeting approximately 100 subjects not taking memantine. The company reported first patient dosing in October 2020 and, as of March 29, 2021, 42 patients enrolled and 17 clinical sites contracted. Estimated trial budget was $9.8 million, with a $2.7 million NIH award intended to reduce the company’s net budgeted cost to $7.1 million.
- COVID-19 could disrupt enrollment, site operations, vendors, and drug supply; the company said it had not experienced significant business or trial delays to date but continued to monitor the risk.
- Key risks include dependence on additional financing, uncertain clinical and regulatory outcomes, limited bryostatin supply, reliance on CRE and contract research organizations, patent uncertainty, and potential dilution. The company reported no legal proceedings against it.
- Spin-off agreements include uncapped reciprocal indemnification obligations. The filing also describes possible tax exposure if the spin-off does not qualify as tax-free; no indemnification claims were reported at the filing date.
- Management concluded disclosure controls and internal control over financial reporting were ineffective at December 31, 2020, citing material weaknesses in segregation of duties, period-end reporting and GAAP disclosure processes, and IT general controls. Management described remediation steps; the auditor did not audit internal control effectiveness.
- The audited financial statements received an unqualified opinion. The filing provides no commercial revenue guidance, and management expects no revenue for the foreseeable future.
Important facts for investors to verify
- Confirm the issuer: the filing is for Synaptogenix, Inc., not TAO Synergies Inc.
- Review the full audited financial statements and reconcile the MD&A’s inconsistent presentation of net loss versus net loss attributable to common shareholders.
- Check current cash, NIH reimbursements, trial spending, enrollment, timelines, and whether additional financing is required beyond the stated 12-month runway.
- Assess the complete clinical data and study design, particularly given the failed confirmatory primary endpoint and reliance on subgroup and post-hoc analyses.
- Review the financing terms, warrant overhang, registration obligations, and resulting dilution, along with progress remediating material weaknesses.